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Letter to the Editor
Low-Dose Sertraline-Induced Erythema
Multiforme in a Child
Mohammad Amjad Ullah Khan, M.D. and Kate Fitzgerald, M.D.
To the Editor:
Introduction
Adverse cutaneous reactions are rare side effects ofserotonin-selective reuptake inhibitors (SSRIs) (Lamoreux et al.
2006). The dermatological side effects include rashes, erythema
multiforme minor, erythema multiforme major or Steven Johnson
syndrome, and toxic epidermal necrolysis (Lamoreux et al. 2006;
Mockenhaupt et al. 2008; Levi et al. 2009). Erythema multiforme is a
dermatological condition that presents with pinkish red blotches
prevalent on the extremities. The lesions are symmetrically placed
and are mildly itching, though rare instances of severe itching may
occur. Generally, erythema multiforme minor resolves within 7–10
days but can develop to erythema multiforme major and life-
threatening Steven Johnson’s syndrome. The classical presentation is
the target lesions, which are composed of a round shape and three
concentric regions; a central reddish area, an edematous pink area, and
an outer lying red ring. The lesions may blister and can have only two
regions, with an absent edematous pink area. The lesions may appear
with varying clinical morphology, several days after the etiological
event, which lends to the nomenclature—(multiforme). The derma-
tological presentation presents on a spectrum varying from only
cutaneous involved erythema minor, to mucosal affected erythema
multiforme major (or Steven-Johnson Syndrome), to severe reaction
of toxic epidermal necrolysis (Lamoreux et al. 2006; Levi et al. 2009).
The proposed etiology is a hypersensitivity reaction, and causative
factors include mycoplasma pneumoniae, herpes simplex virus in-
fections, autoimmune diseases, and medications (Lamoreux et al.
2006; Mockenhaupt et al. 2008; Levi et al. 2009). SSRIs have rarely
been implicated with sertraline, the only drug cited for Steven Johnson
syndrome and toxic epidermal necrolysis (Bodokh et al. 1992;
Mockenhaupt et al. 2008; Lange-Asschenfeldt et al. 2009; Levi et al.
2009). Sertraline has been reported in six cases, all of whom were
adults (Gales and Gales 1994; Beauquier and Fahs 1998; Jan et al.
1999; Thédenat et al. 2001; Lange-Asschenfeldt et al. 2009). We
present sertraline-induced erythema multiforme in a 9-year-old boy,
which to our knowledge is the only case described in a child.
Case Report
J. is a 9-year-old boy of Caucasian descent who presented to the
outpatient psychiatry clinic with complaints of excessive worrying
daily about multiple things. He worried about his mother’s health,
harm befalling her, his own health, catching the few, or having
cancer. He slept well during the night, but in the bed in his mother’s
bedroom while his mother slept on the couch. He had occasionally
refused going to school by using somatic complaints of stomach
ache and headache. He sought reassurance from his mother every
day that she would pick him up from school. He ate well though he
was selective in his choices. He enjoyed playing with his sister and
her friends, but had only a few friends of his own. He had good
focus and concentration, organized his tasks, and followed direc-
tions at school and at home. He had never seen a psychiatrist. His
mental status examination was unremarkable. A review of health
systems revealed abdominal migraine and restless leg syndrome for
which he had been taking cyproheptadine for 22 months and ferrous
sulfate for 11 months, respectively. He had tolerated both the
medications well with no adverse effects. He had tried nortriptyline
for headache, but discontinued it 11 months earlier due to lack of
efficacy. No drug or food allergies were reported. Vital signs were
stable. Laboratory tests including lipid panel, comprehensive elec-
trolytes, and complete blood count with differential were essentially
within normal limits. Rating scales employed included Multi-
dimensional Anxiety Scale for Children, Child Behavior Checklist,
and Social Communications Questionnaire. Results of the rating
scales were consistently higher in anxiety domains. A diagnosis of
generalized anxiety disorder, separation anxiety disorder with a rule
out of obsessive compulsive disorder was established.
A comprehensive treatment plan was discussed with the mother
and the patient. We discussed pharmacological treatment and in-
dividual psychotherapy. The mother agreed to the choice of ser-
traline with the patient’s assent. The patient was enrolled in
individual psychotherapy, and medication treatment was started
with sertraline 25 mg every day with a plan to follow up in 10 days.
Two days after starting sertraline, the patient’s mother noticed a
rash on his back and chest. She took the patient to his pediatrician’s
office where the physical examination revealed more spots on his
arms and legs. The rash was mainly in the trunk area and was not
itchy, painful, or bothersome to the patient. Diagnostic target le-
sions of erythema multiforme were observed. These lesions con-
sisted of a dark central papule, with a pale immediate area
surrounded by peripheral eythemous area. The mother or child did
not report hives, welts, lip swelling, wheezing, or difficulty in
breathing. His outpatient psychiatrist (the author) was contacted,
and it was decided to discontinue sertraline with an immediate
follow up in the outpatient psychiatry clinic for reassessment. On
follow up at the child psychiatry outpatient clinic, a few days later,
the patient was seen to have resolving rash with very discreet le-
sions, mainly on the trunk. Treatment choices were discussed with
the mother again. We were concerned that sertraline triggered the
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erythema multiforme reaction and that it could have progressed to
Steven Johnson syndrome or toxic epidermal necrolysis. It has been
hypothesized in literature that cross reactivity among different
SSRI may be present; however, no conclusive supportive data are
available. Bearing in mind that the best evidence-based medication
treatment for the patient’s diagnoses was an SSRI, we decided not
to rechallenge with sertraline and cautiously initiated citalopram.
Clinical decision making was also influenced by therapeutic alli-
ance with the patient and his family and which led the prescribing
physician to feel that the patient would inform us of any unusual
reactions. We provided our contact information and the emergency
room information to the patient with explicit instructions to call or
show up in case of concerns. The patient tolerated citalopram well
and was followed up regularly for medication monitoring every few
weeks. He has continued to show improvement in anxiety issues.
Dermatological adverse effects are fully resolved with no sequelae.
Discussion
This case raises many important aspects of clinical care. This
case provides insight into selection of an SSRI after adverse reac-
tion to initial choice. The patient most likely developed an adverse
reaction to sertraline that had just been initiated before the onset of
rash, rather than cyproheptadine and ferrous sulfate which were
started months earlier with no side effects. The patient tolerated
citalopram well without any difficulty even though it is an SSRI in
the same class as sertraline. This case demonstrates the potential
association of sertraline with erythema multiforme, and suggests
that switching to another SSRI may be a safe and effective option if
sertraline induced rash occurs. Communication and accessibility to
this young patient and his mother enabled early intervention and
effective change to a different SSRI to achieve control of the pa-
tient’s anxiety symptoms. A good therapeutic alliance helped foster
treatment decisions and highlights the importance of forming
physician-patient relationship with young patients.
This case report points to clinically significant information that
will help foster treatment decisions, but more research will be ex-
tremely valuable in the subject of SSRI adverse effects.
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RR, Rüther E, Cordes J: Cutaneous adverse reactions to psycho-
tropic drugs: Data from a multicenter surveillance program. J Clin
Psychiatry 70:1258–1265, 2009.
Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A,
Kelly JP, Martin E, Kaufman DW, Maison P: Medications as risk
factors of Stevens-Johnson syndrome and toxic epidermal necro-
lysis in children: A pooled analysis. Pediatrics 123:e297–e304,
2009.
Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes
Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A:
Stevens-Johnson syndrome and toxic epidermal necrolysis:
Assessment of medication risks with emphasis on recently
marketed drugs. The EuroSCAR-study. J Invest Dermatol 128:
35–44, 2008.
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